“We are very pleased with our execution in 2012,” stated Jay Flatley, President and CEO. “We ended the year with a strong performance, and made significant progress on our strategy of growing our clinical business, both organically and through acquisition. We remain optimistic about our growth prospects in 2013 and beyond, in spite of the continuing challenges of the economic environment.”

Highlights since our last earnings release
  • Announced a definitive agreement to acquire Verinata Health, Inc., a leading provider of non-invasive tests for the early identification of fetal chromosomal abnormalities
  • Completed the acquisition of Moleculo Inc., which will enable the introduction of a novel library prep method and analysis algorithm to produce synthetic read lengths up to 10 Kb
  • Previewed a new, ordered array flow cell technology that will provide a significant increase in cluster density and number of reads per flow cell
  • Announced a new kit for the HiSeq® 2500 which is capable of generating up to 300 Gb in rapid mode
  • Presented an updated MiSeq® roadmap with chemistry and software enhancements to deliver 15 Gb of throughput
  • Announced Nextera® Rapid Capture Exome Kits to provide the fastest exome enrichment workflow on both the HiSeq 2500 and MiSeq
  • Launched TruSeq® DNA PCR-Free Kits, a simple, all-inclusive sample prep solution for whole-genome sequencing
  • Announced TruSeq Targeted RNA Kits for mid-plex gene expression profiling and validation
  • Announced that Caris Life Sciences has selected the MiSeq system to support Caris' evidence-based molecular profiling service
  • Announced that VWR International, LLC, will distribute Illumina's qPCR portfolio within the United States
  • Announced winners of the MiSeq grant program to accelerate original research in microbial ecology, neglected disease, and human health
  • Named Dr. Robert S. Epstein to the Board of Directors
  • Announced a favorable ruling in patent litigation against Complete Genomics, Inc.
  • Announced new grant recipients of our Agricultural Greater Good Initiative at the 21st International Plant and Animal Genome Conference
  • Repurchased $25 million of common stock under our previously announced share repurchase program

Financial outlook and guidance

The non-GAAP financial guidance discussed below excludes various one-time or specified non-cash charges. Please see our Reconciliation of Non-GAAP Financial Guidance included in this release for a reconciliation of the GAAP and Non-GAAP financial measures.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement